77 related articles for article (PubMed ID: 29577693)
1. [Tat-based cell-cell fusion method for screening HIV-1 fusion inhibitors].
Wang X; Yang Y; Shen S; Wang X; Feng T; Hu Q; Zeng Y
Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):429-439. PubMed ID: 29577693
[TBL] [Abstract][Full Text] [Related]
2. An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors.
Herschhorn A; Finzi A; Jones DM; Courter JR; Sugawara A; Smith AB; Sodroski JG
PLoS One; 2011; 6(11):e26731. PubMed ID: 22069466
[TBL] [Abstract][Full Text] [Related]
3. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
5. [A non-infectious and quantitative cell-based bioassay for screening HIV entry inhibitors targeting HIV envelope proteins].
Li MM; Xia CL; Mao QC; Jiang SB; Liu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):941-4. PubMed ID: 20501362
[TBL] [Abstract][Full Text] [Related]
6. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
7. Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry.
Bradley J; Gill J; Bertelli F; Letafat S; Corbau R; Hayter P; Harrison P; Tee A; Keighley W; Perros M; Ciaramella G; Sewing A; Williams C
J Biomol Screen; 2004 Sep; 9(6):516-24. PubMed ID: 15452338
[TBL] [Abstract][Full Text] [Related]
8. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 entry inhibitors: an overview.
Kuritzkes DR
Curr Opin HIV AIDS; 2009 Mar; 4(2):82-7. PubMed ID: 19339945
[TBL] [Abstract][Full Text] [Related]
10. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
[TBL] [Abstract][Full Text] [Related]
11. HIV entry inhibitors and their potential in HIV therapy.
Qian K; Morris-Natschke SL; Lee KH
Med Res Rev; 2009 Mar; 29(2):369-93. PubMed ID: 18720513
[TBL] [Abstract][Full Text] [Related]
12. Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors.
Giroud C; Du Y; Marin M; Min Q; Jui NT; Fu H; Melikyan GB
Assay Drug Dev Technol; 2017; 15(2):53-63. PubMed ID: 28322598
[TBL] [Abstract][Full Text] [Related]
13. The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.
Flynn JK; Paukovics G; Moore MS; Ellett A; Gray LR; Duncan R; Salimi H; Jubb B; Westby M; Purcell DF; Lewin SR; Lee B; Churchill MJ; Gorry PR; Roche M
Virology; 2013 Jul; 442(1):51-8. PubMed ID: 23602007
[TBL] [Abstract][Full Text] [Related]
14. HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4.
Smith EB; Ogert RA; Pechter D; Villafania A; Abbondanzo SJ; Lin K; Rivera-Gines A; Rebsch-Mastykarz C; Monsma FJ
J Biomol Screen; 2014 Jan; 19(1):108-18. PubMed ID: 23989454
[TBL] [Abstract][Full Text] [Related]
15. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
Yost R; Pasquale TR; Sahloff EG
Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
[TBL] [Abstract][Full Text] [Related]
16. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli.
Pusch O; Kalyanaraman R; Tucker LD; Wells JM; Ramratnam B; Boden D
AIDS; 2006 Oct; 20(15):1917-22. PubMed ID: 16988512
[TBL] [Abstract][Full Text] [Related]
17. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
18. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication.
Ochsenbauer-Jambor C; Jones J; Heil M; Zammit KP; Kutsch O
Biotechniques; 2006 Jan; 40(1):91-100. PubMed ID: 16454046
[TBL] [Abstract][Full Text] [Related]
19. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
